ScoreWhy is Basilea Pharmaceutica AG ?
1
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.92
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.92
- The company has been able to generate a Return on Equity (avg) of 31.93% signifying low profitability per unit of shareholders funds
2
Healthy long term growth as Net Sales has grown by an annual rate of 12.73% and Operating profit at 33.35%
3
Flat results in Jun 25
- RAW MATERIAL COST(Y) Grown by 13.23% (YoY)
4
With ROE of 70.44%, it has a Very Expensive valuation with a 6.27 Price to Book Value
- Over the past year, while the stock has generated a return of 12.75%, its profits have risen by 7331%
5
Market Beating Performance
- Even though the market (Switzerland SMI) has generated negative returns of -1.34% in the last 1 year, the stock has been able to generate 12.75% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Basilea Pharmaceutica AG should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Basilea Pharmaceutica AG for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Basilea Pharmaceutica AG
12.75%
1.01
30.63%
Switzerland SMI
1.42%
-0.08
16.69%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.73%
EBIT Growth (5y)
33.35%
EBIT to Interest (avg)
1.92
Debt to EBITDA (avg)
10.62
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
1.11
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
40.20%
ROE (avg)
31.93%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
6.27
EV to EBIT
7.88
EV to EBITDA
7.52
EV to Capital Employed
10.99
EV to Sales
2.53
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
139.41%
ROE (Latest)
70.44%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CHF 89.8 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 1.66 times
PRE-TAX PROFIT(Q)
At CHF 19.34 MM has Grown at 164.1%
CASH AND EQV(HY)
Highest at CHF 132.72 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 4.45 times
NET SALES(Q)
At CHF 103.96 MM has Grown at 36.26%
-1What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 13.23% (YoY
Here's what is working for Basilea Pharmaceutica AG
Operating Cash Flow
Highest at CHF 89.8 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CHF MM)
Pre-Tax Profit
At CHF 19.34 MM has Grown at 164.1%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CHF MM)
Inventory Turnover Ratio
Highest at 1.66 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Net Sales
At CHF 103.96 MM has Grown at 36.26%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CHF MM)
Cash and Eqv
Highest at CHF 132.72 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 4.45 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Depreciation
Highest at CHF 1.87 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (CHF MM)
Here's what is not working for Basilea Pharmaceutica AG
Raw Material Cost
Grown by 13.23% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
